World Health Organization Issues Concern Over Acute Shortage of Obesity Injections
Under a tenth of people who could benefit from obesity jabs including Wegovy have access to them, warns the global health agency as it issues its inaugural advice on the medications.
Given in excess of 1,000,000,000 people worldwide now obese, it is calling for broader and more equitable access to these injectable treatments.
Per estimates, more than two billion are projected to be living with obesity by 2030 unless action is taken.
"The new guidance acknowledges that obesity is a long-term condition that can be addressed with holistic and ongoing treatment," remarked its chief Tedros Adhanom Ghebreyesus.
High costs, insufficient output, and supply-chain constraints are key hurdles to universal access to the treatments that can help people shift significant weight, notes the body.
Skinny Jab Shortage
Despite the present best projected case, the supply of GLP-1 therapies could only cover about 100 million people – less than 10% of eligible patients, as stated by the health organization.
The advice calls on governments and firms to expand availability, by strategies such as patent sharing.
The intellectual property rights on semaglutide – the main component of Novo Nordisk's Wegovy – is set to lapse in a number of countries in 2026.
The Way Weight-Loss Drugs Work
GLP-1 drugs imitate a biological compound to delay gastric emptying, suppress the appetite and boost the sense of being full so users reduce food intake.
Individuals usually see weight reduction after several weeks of beginning the weekly injections.
Studies points to people may regain a significant portion after a year of stopping the medication, as their normal food cravings return.
To be carrying excess weight elevates your risk for contracting health problems, such as diabetes, cardiovascular issues, stroke, and certain cancers.
Obesity affects individuals in countries worldwide and was responsible for millions of fatalities worldwide in 2024, according to the health agency.
